Surgical Science Sweden Ab · OMXSTO:SUS
Surgical Science Sweden Ab — Q2 2026 Earnings Presentation
12 slides from Surgical Science Sweden Ab's earnings presentation, Aug 19, 2026
Slide 1: Presentation of Interim Report Q2
Presentation of Interim Report Q2 ©2025 Surgical Science. | All rights reserved.
Slide 2: CEO comments – Q2 2026
CEO comments – Q2 2026 Revenue Adjusted EBIT ▪ Strong financial and operational results SEK 254.5m SEK 38.2m ▫ Revenue growth of 25% in local currencies +22% reported | +25% fx- 15% margin | 14% fx-adj ▫ Adjusted EBIT at 15%, in line with financial target adj. ▪ Educational Products 24% growth in lo
Slide 3: Society for Robotic Surgery event
This year’s event, Society for Robotic Surgery (Orlando, FL), generated strong interest in our product and services, and a record number of attendees and exhibitors.
Slide 4: CEO comments – Q2 2026
CEO comments – Q2 2026 Revenue Adjusted EBIT ▪ Strong financial and operational results SEK 254.5m SEK 38.2m ▫ Revenue growth of 25% in local currencies +22% reported | +25% fx- 15% margin | 14% fx-adj ▫ Adjusted EBIT at 15%, in line with financial target adj. ▪ Educational Products 24% growth in lo
Slide 5: Q2: Strong license revenues and improved profitability
Q2: Strong license revenues and improved profitability SEKm 250 Q2: ▪ Net sales up 22% to SEKm 254.5 (209.2). In local currencies up 25%. 200 47% 52% 50% 48% 51% 45% ▪ Educational Products up 19%, 24% excl. FX. 45% 48% 47% Regions: EMEA +60%, APAC +10%, Americas +4%. 150 ▪ Industry up 24%, 27% excl.
Slide 6: Revenue streams
Revenue streams SEKm 8% 2% 4% 8% 250 6% 4% Q2: 6% 4% 11% 200 30% 25% 34% ▪ License revenues: 33% (28) of total revenues. 33% 33% 28% 29% Intuitive revenues for H1 in line with H1 2025 in 32% 9% USD. Assessment that total revenue loss due to 8% 28% 150 10% 9% cancelled MoU will be less than the inter
Slide 7: Costs and EBIT margin
Costs and EBIT margin Q2: ▪ Gross margin 69% (65). Higher license revenue, increased direct sales within Edu and price increases had a positive effect. Costs/margin as a percentage of sales ▪ Sales: 19% (28) of sales. SEKm 1.2 in tariff refunds relating to the corresponding quarter in 2025. Cost of
Slide 8: Organization
Organization No of employees at end of period: 319 (327) Men 226 (232) Women 93 (95 ) Israel 155 (147) Sweden 76 (69) USA 38 (58) UK 28 (35) Other 22 (18) * Offices / Development sites * Other : Primarily Germany and China. 5
Slide 9: Adjusted EBIT
Adjusted EBIT* SEKm 50% Q2: 250 200 40% ▪ Adjusted EBIT SEKm 38.2 (- 16.7), 15% ( - 8). 150 30% ▪ FX - adjusted adjusted EBIT 20% SEKm 34.3, 14%. 100 H1: 50 10% ▪ Adjusted EBIT SEKm 66.5 0 0% (13.4), 14% (3). Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2024 2025 2026 -50 -10% ▪ FX - adjusted adjusted EBIT SEKm 76.8,
Slide 10: Finance net and taxes
Finance net and taxes Q2: ▪ Finance net SEKm - 0.9 (3.7). Interest on bank balances, revaluation of internal loans and IFRS 16 effect. ▪ Tax expense SEKm 10.9 (1.4). ▪ Net result SEKm 20.8 ( - 20.1). H1: ▪ Finance net SEKm - 2.1 (25.9). ▪ Tax expense SEKm 13.9 (14.3). ▪ Net result SEKm 39.5 (13.2).
Slide 11: Cash flow
Cash flow Q2: ▪ Cash flow from operating activities SEKm 15.3 800 18% (16.2). Change in working capital SEKm - 20.8 (20.0). Inventory, A/R and current receivables 700 16% increased. 14% 600 ▪ Cash flow from investing activities SEKm - 21.8 12% (- 12.6) mainly investments in development 500 costs. SE
Slide 12: Thank you
Thank you Find out more at: www.surgicalscience.com ©2026 Surgical Science. | All rights reserved.
Surgical Science Sweden — Q2 2026 Earnings Presentation on 6ix